Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold(St. Josef-Hospital), Gilmore O’Neill(Biogen (United States)), Randy Robinson(AbbVie (United States)), Ernst‐Wilhelm Radue, Katherine Riester(Biogen (United States)), Dusan Stefoski(Rush University Medical Center), Eva Havrdová(Charles University), Jacob Elkins(Biogen (United States)), Jitesh Rana(Biogen (United States)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Gavin Giovannoni(Queen Mary University of London), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn)
Cited by 287
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k